search
Back to results

Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS) (DESIRE-ACS)

Primary Purpose

Coronary Disease, Acute Coronary Syndrome, Coronary Occlusion

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Bell Balloon Catheter
Sponsored by
Angioslide Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Disease focused on measuring Acute Coronary Syndrome, Coronary Occlusion, catheter

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Clinical criteria

  1. Subject is ≥18 years of age.
  2. Subject with acute coronary syndrome (STEMI or NSTEMI).
  3. Candidate for percutaneous coronary intervention (PCI) in native coronary artery.
  4. Anticipated patient life expectancy of at least 1 year since enrollment.
  5. Subject is male or a non-pregnant female.
  6. Subject has provided written informed consent.
  7. Subject is able and willing to adhere to the required follow-up visits and testing.

Angiographic Criteria

  1. Lesions amendable to PCI.
  2. Angiographically thrombotic-appearing lesion that amenable to PCI.
  3. Lesion(s) is located within the native vessel and has ≥ 50% but <100% stenosis.
  4. The target lesion should be at least 10mm proximal to the proximal edge of a stented lesion.
  5. Only a single lesion will be treated by the investigational device.
  6. Vessel has thrombolysis in myocardial infarction (TIMI) grade 1 or higher flow before the use of the investigational device.
  7. Reference vessel diameter, where the Bell balloon is to be placed, is 3-4mm in diameter by angiographic visual estimation.

Exclusion Criteria:

Clinical Criteria

  1. Women except those whose menstrual periods have not occurred for more than one year after menopause or those who have had sterilization surgery (tubal ligation) or hysterectomy
  2. Known contraindication to the use of heparin or bivalirum (Angiomax).
  3. Known contraindication to the use of dual anti-platelet therapy
  4. Known hypersensitivity to contrast media which cannot be adequately pretreated.
  5. Subject has renal insufficiency, defined as baseline creatinine level ≥ 2.0 mg/dl.
  6. Subject has a known history of neutropenia (WBC <3,000/mm3) or significant anemia.
  7. Subjects has a known history of coagulopathy or thrombophilia [prothrombin International Normalized Ratio (INR)>1.5, Platelet count<80,000/ μL], that has not resolved or has required treatment in the past 6 months.
  8. Major bleeding within 6 months of index procedure.
  9. A planned invasive surgical procedure within 30 days.
  10. Undergone cardiac surgery within the past 30 days or has a planned surgical procedure within 30 days from study procedure
  11. Left ventricular ejection fraction < 25%
  12. The patient is in cardiogenic shock or hemodynamic unstable
  13. Cerebrovascular Accident (CVA) or TIA within the past 6 months.
  14. Exclusions that preclude placement of the bell balloon per the Instruction for Use
  15. Subject not capable of understanding and signing the Informed Consent form.

Angiographic Criteria

  1. Anatomical exclusions that preclude placement of the bell balloon per the Instruction for Use.
  2. Target lesion inside or within 10mm of a prior stent
  3. Target lesion distal to a prior placed stent
  4. Severe calcification at the lesion site or proximal to it.
  5. Aorto-ostial lesions
  6. Bifurcation lesions (side branch diameter ≥ 2.0mm)
  7. Severe coronary artery tortuosity (Angulation >450)
  8. Target lesion is totally occluded, or Thrombolysis in Acute MI (TIMI flow 0) despite pre-dilatation with small caliber balloon
  9. Coronary artery spasm in the absence of a significant stenosis

Sites / Locations

  • Shaare Zedek Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bell Balloon Catheter

Arm Description

The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.

Outcomes

Primary Outcome Measures

The rate of major adverse cardiac events (MACE)
Defined as a composite of cardiac death, all myocardial infarction (Q wave and non-Q wave), and target lesion revascularization (PCI and CABG)
Angiographic and Device Success
Defined as patent vessel with stenosis <50% with a final TIMI flow grade 3 (visually assessed by angiography) without side branch loss, flow-limiting dissection, or angiographic thrombus and embolic material retrieval. Thrombolysis In Myocardial Infarction (TIMI) flow grade at the end of the revascularization procedure, compared to baseline. ST resolution level in patients with ST-Elevation Myocardial Infarction (STEMI). Myocardial Blush Grade (MBG) at the end of procedure, compared to baseline
Performance - Device success
Defined as ability to deliver, deploy, and intact retract retrieval of the study device and retrieve embolic material

Secondary Outcome Measures

Full Information

First Posted
December 22, 2014
Last Updated
July 26, 2015
Sponsor
Angioslide Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02325869
Brief Title
Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS)
Acronym
DESIRE-ACS
Official Title
DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to Assess the Safety and Performance of the ECA Bell Balloon in Subjects Undergoing Coronary Percutaneous Interventions.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
March 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Angioslide Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to assess the safety and performance of the ECA Bell balloon in subjects undergoing coronary percutaneous interventions.
Detailed Description
Coronary arterial disease (CAD) is defined as obstruction of blood flow into the coronary arteries (i.e. the arteries that supply blood to the heart muscle). Patients with symptoms of coronary artery disease usually suffer from stable angina pectoris (chest pain or discomfort), unstable angina pectoris, or a myocardial infarction (heart attack). The symptoms range from mild angina, to moderate or severe angina. In some cases of CAD the blood vessel is chronically totally blocked (total occlusion), stopping blood flow through the blocked blood vessel. In these cases a minimally invasive treatment or a surgery may be needed. "Minimally invasive procedures" consist of angioplasty or stent placement. The procedure is performed under local anesthetic with the patient lying on their back. Angioplasty is a routine, well known, non-surgical procedure that is performed by making a small incision of the skin in the groin through which a catheter (narrow tube) and a guidewire (a thin metal wire) are inserted to reach the blocked artery. After reaching the blocked artery and crossing the blockage with a guidewire, a tiny balloon is inflated inside the artery to open the blockage. During the course of this procedure small pieces of the material that is causing the blockage may break off and be carried by the blood stream to other parts of the body where they may lodge and cause damage by blocking the blood flow . The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Disease, Acute Coronary Syndrome, Coronary Occlusion
Keywords
Acute Coronary Syndrome, Coronary Occlusion, catheter

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bell Balloon Catheter
Arm Type
Experimental
Arm Description
The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
Intervention Type
Device
Intervention Name(s)
Bell Balloon Catheter
Intervention Description
An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
Primary Outcome Measure Information:
Title
The rate of major adverse cardiac events (MACE)
Description
Defined as a composite of cardiac death, all myocardial infarction (Q wave and non-Q wave), and target lesion revascularization (PCI and CABG)
Time Frame
Up to 30 (+/-7) days post procedure
Title
Angiographic and Device Success
Description
Defined as patent vessel with stenosis <50% with a final TIMI flow grade 3 (visually assessed by angiography) without side branch loss, flow-limiting dissection, or angiographic thrombus and embolic material retrieval. Thrombolysis In Myocardial Infarction (TIMI) flow grade at the end of the revascularization procedure, compared to baseline. ST resolution level in patients with ST-Elevation Myocardial Infarction (STEMI). Myocardial Blush Grade (MBG) at the end of procedure, compared to baseline
Time Frame
During procedure and up to 30 (+/-7) days post procedure
Title
Performance - Device success
Description
Defined as ability to deliver, deploy, and intact retract retrieval of the study device and retrieve embolic material
Time Frame
During procedure and up to 30 (+/-7) days post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical criteria Subject is ≥18 years of age. Subject with acute coronary syndrome (STEMI or NSTEMI). Candidate for percutaneous coronary intervention (PCI) in native coronary artery. Anticipated patient life expectancy of at least 1 year since enrollment. Subject is male or a non-pregnant female. Subject has provided written informed consent. Subject is able and willing to adhere to the required follow-up visits and testing. Angiographic Criteria Lesions amendable to PCI. Angiographically thrombotic-appearing lesion that amenable to PCI. Lesion(s) is located within the native vessel and has ≥ 50% but <100% stenosis. The target lesion should be at least 10mm proximal to the proximal edge of a stented lesion. Only a single lesion will be treated by the investigational device. Vessel has thrombolysis in myocardial infarction (TIMI) grade 1 or higher flow before the use of the investigational device. Reference vessel diameter, where the Bell balloon is to be placed, is 3-4mm in diameter by angiographic visual estimation. Exclusion Criteria: Clinical Criteria Women except those whose menstrual periods have not occurred for more than one year after menopause or those who have had sterilization surgery (tubal ligation) or hysterectomy Known contraindication to the use of heparin or bivalirum (Angiomax). Known contraindication to the use of dual anti-platelet therapy Known hypersensitivity to contrast media which cannot be adequately pretreated. Subject has renal insufficiency, defined as baseline creatinine level ≥ 2.0 mg/dl. Subject has a known history of neutropenia (WBC <3,000/mm3) or significant anemia. Subjects has a known history of coagulopathy or thrombophilia [prothrombin International Normalized Ratio (INR)>1.5, Platelet count<80,000/ μL], that has not resolved or has required treatment in the past 6 months. Major bleeding within 6 months of index procedure. A planned invasive surgical procedure within 30 days. Undergone cardiac surgery within the past 30 days or has a planned surgical procedure within 30 days from study procedure Left ventricular ejection fraction < 25% The patient is in cardiogenic shock or hemodynamic unstable Cerebrovascular Accident (CVA) or TIA within the past 6 months. Exclusions that preclude placement of the bell balloon per the Instruction for Use Subject not capable of understanding and signing the Informed Consent form. Angiographic Criteria Anatomical exclusions that preclude placement of the bell balloon per the Instruction for Use. Target lesion inside or within 10mm of a prior stent Target lesion distal to a prior placed stent Severe calcification at the lesion site or proximal to it. Aorto-ostial lesions Bifurcation lesions (side branch diameter ≥ 2.0mm) Severe coronary artery tortuosity (Angulation >450) Target lesion is totally occluded, or Thrombolysis in Acute MI (TIMI flow 0) despite pre-dilatation with small caliber balloon Coronary artery spasm in the absence of a significant stenosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eran Vickus
Phone
+972 9 7904609
Email
eranv@angioslide.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giora Weisz, Prof. M.D
Organizational Affiliation
Chairman, Department of Cardiology. Shaare Zedek Medical Center, Jerusalem Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shaare Zedek Medical Center
City
Jerusalem
ZIP/Postal Code
9103102
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giora Weisz, Prof., MD
Phone
972.2.6555.975
Email
cardio@szmc.org.il

12. IPD Sharing Statement

Learn more about this trial

Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS)

We'll reach out to this number within 24 hrs